Treatment of Prostate Cancer by Targeting PI3K/Akt Signaling Pathway with Traditional Chinese Medicine： A Review
10.13422/j.cnki.syfjx.20241892
- VernacularTitle:中医药干预PI3K/Akt信号通路治疗前列腺癌研究进展
- Author:
Shenglong LI
1
;
Dacheng TIAN
1
;
Jie GAO
1
;
Ganggang LU
1
;
Hui LI
1
;
Yuanbo ZHAO
1
;
Meisheng GONG
2
;
Yongqiang ZHAO
3
;
Yunpeng JIA
3
;
Yonglin LIANG
4
Author Information
1. School of Traditional Chinese and Western Medicine， Gansu University of Chinese Medicine，Lanzhou 730000，China
2. Graduate School， Heilongjiang Academy of Chinese Medicine，Harbin 150006，China
3. Gansu Provincial Hospital of Traditional Chinese Medicine，Lanzhou 730050，China
4. School of Basic Medicine，Gansu University of Chinese Medicine，Lanzhou 730000，China
- Publication Type:Journal Article
- Keywords:
prostate cancer;
phosphatidylinositol 3-kinase （PI3K）/protein kinase B （Akt）;
signaling pathway;
traditional Chinese medicine;
research progress
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2024;30(15):290-298
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer （PCa） is one of the most common malignant tumors in the male genitourinary system. The phosphatidylinositol 3-kinase （PI3K）/protein kinase B （Akt） signaling pathway is a carcinogenic pathway responsible for the migration， proliferation， and drug resistance of various cancers. In recent years， as the research on the pathogenesis of PCa is deepening， the role of the PI3K/Akt signaling pathway in the development of PCa has attracted much attention. Traditional Chinese medicine， comprehensively regulating multiple components， targets， and pathways， has shown great potential in the treatment of PCa. This article reviews the research progress of traditional Chinese medicine targeting the PI3K/Akt signaling pathway in the treatment of PCa and discusses the expression of the PI3K/Akt signaling pathway in PCa， which involves inhibiting apoptosis of PCa cells， promoting the cell cycle， invasion， and migration of PCa cells， promoting tumor tissue angiogenesis， and mediating the androgen receptor. Additionally， it summarizes the single Chinese medicines that target and regulate this pathway， including Hedyotis diffusa， Taxus chinensis， Bovisc Alculus， and Atractylodis Macrocephalae Rhizoma. The active ingredients of these Chinese medicines mainly include flavonoids， alkaloids， terpenes， polyphenols， lignans， and other compounds. The Chinese medicine compound prescriptions targeting the PI3K/Akt pathway mainly include Wenshen Sanjie prescription， Jianspi Lishi Huayu prescription， Yishen Tonglongtang， Qilan prescription， Xihuangwan， and modified Shenqi Dihuangtang. This review is expected to provide a scientific basis for deeply understanding the pathogenesis of PCa and identifying potential therapeutic targets， as well as to provide new ideas for clinical research and drug development for PCa.
